chitosan has been researched along with Anthrax in 5 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 1 (20.00) | 29.6817 |
2010's | 3 (60.00) | 24.3611 |
2020's | 1 (20.00) | 2.80 |
Authors | Studies |
---|---|
Chen, CC; Chen, XA; Cheng, KM; Chuang, CC; Kau, JH; Lee, CY; Shyu, HF; Tsai, MH; Yen, HJ; Young, JJ | 1 |
Agrawal, U; Jain, AK; Mangal, S; Pawar, D; Vyas, SP | 1 |
Chen, X; Liu, Y; Ma, G; Wang, L; Xu, J; Yang, X; Yin, Y; Zhang, W | 1 |
Bento, D; Borges, O; Gonçalves, T; Staats, HF | 1 |
Cheff, A; Hinchcliffe, M; Petrie, CR; Richardson, C; Stenz, JP; Tino, WT; Warwood, SJ; Williams, MS; Wimer-Mackin, S | 1 |
5 other study(ies) available for chitosan and Anthrax
Article | Year |
---|---|
Nanoparticles assembled from fucoidan and trimethylchitosan as anthrax vaccine adjuvant: In vitro and in vivo efficacy in comparison to CpG.
Topics: A549 Cells; Adjuvants, Immunologic; Animals; Anthrax; Anthrax Vaccines; Bacillus anthracis; Chitosan; Cytokines; Female; Humans; Mice; Nanoparticles; Oligodeoxyribonucleotides; Polysaccharides | 2020 |
Evaluation of mucoadhesive carrier adjuvant: toward an oral anthrax vaccine.
Topics: Adjuvants, Immunologic; Administration, Oral; Alginates; Animals; Anthrax; Anthrax Vaccines; Antibodies, Bacterial; Antigens, Bacterial; Bacillus anthracis; Bacterial Toxins; Biomimetic Materials; Chitosan; Female; Gastric Juice; Immunity, Innate; Immunity, Mucosal; Mice; Mice, Inbred BALB C; Neutralization Tests; Peyer's Patches; Vaccination | 2014 |
Engineering biomaterial-associated complement activation to improve vaccine efficacy.
Topics: Adjuvants, Immunologic; Animals; Anthrax; Antibody Formation; Cell Proliferation; Cells, Cultured; Chitosan; Complement Activation; Cytokines; Female; Humans; Mice; Mice, Inbred BALB C; Microspheres; Particle Size; Surface Properties; T-Lymphocytes; Vaccine Potency | 2013 |
Development of a novel adjuvanted nasal vaccine: C48/80 associated with chitosan nanoparticles as a path to enhance mucosal immunity.
Topics: Adjuvants, Immunologic; Administration, Intranasal; Alginates; Animals; Anthrax; Anthrax Vaccines; Antibodies, Bacterial; Antigens, Bacterial; Bacterial Toxins; Biomarkers; Chemistry, Pharmaceutical; Chitosan; Dose-Response Relationship, Drug; Drug Carriers; Female; Glucuronic Acid; Hexuronic Acids; Humans; Immunity, Mucosal; Immunization; Mast Cells; Mice; Mice, Inbred C57BL; Nanomedicine; Nanoparticles; Nasal Mucosa; p-Methoxy-N-methylphenethylamine; Particle Size; RAW 264.7 Cells; Surface Properties; T-Lymphocytes, Helper-Inducer; Technology, Pharmaceutical; Time Factors | 2015 |
An intranasal vaccine targeting both the Bacillus anthracis toxin and bacterium provides protection against aerosol spore challenge in rabbits.
Topics: Adjuvants, Immunologic; Administration, Intranasal; Aerosols; Animals; Anorexia; Anthrax; Anthrax Vaccines; Antibodies, Bacterial; Antigens, Bacterial; Bacillus anthracis; Bacterial Capsules; Bacterial Toxins; Chitosan; Disease Models, Animal; Enzyme-Linked Immunosorbent Assay; Female; Immunoglobulin G; Inhalation Exposure; Lipid A; Neutralization Tests; Polyglutamic Acid; Rabbits; Recombinant Fusion Proteins | 2006 |